Literature DB >> 25956032

Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.

Ze-Hua Zuo1, Yan P Yu1, Ying Ding2, Silvia Liu2, Amantha Martin1, George Tseng2, Jian-Hua Luo3.   

Abstract

Cellular stress response 1 (CSR1) is a tumor suppressor gene whose expression was frequently down-regulated in prostate cancer. The mechanism of its down-regulation, however, is not clear. Here, we show that the 3' untranslated region of CSR1 contains a target site of miR-650. High level of miR-650 was found in prostate cancer samples and cell lines. Degradation of miR-650 by specific inhibitor dramatically increased the expression levels of CSR1. Interaction between miR-650 and its target site in the 3' untranslated region was validated through luciferase reporter system. Mutation at the target site completely abrogated the activity of miR-650 on the 3' untranslated region of CSR1. Inhibition of miR-650 reversed the expression suppression of CSR1, suppressed colony formation, and blocked cell cycle entry to the S phase of both PC3 and DU145 cells. Animal model showed significant decrease of tumor volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC3 or DU145 cells transformed with inhibitor of miR-650. Our analyses demonstrate that suppression of CSR1 expression is a novel mechanism critical for the oncogenic activity of miR-650.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25956032      PMCID: PMC4484220          DOI: 10.1016/j.ajpath.2015.03.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Evidence that polyadenylation factor CPSF-73 is the mRNA 3' processing endonuclease.

Authors:  Kevin Ryan; Olga Calvo; James L Manley
Journal:  RNA       Date:  2004-04       Impact factor: 4.942

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 3.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

4.  Gene expression analysis of prostate cancers.

Authors:  Jian-Hua Luo; Yan Ping Yu; Kathleen Cieply; Fan Lin; Petrina Deflavia; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich
Journal:  Mol Carcinog       Date:  2002-01       Impact factor: 4.784

5.  Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer.

Authors:  Yan P Yu; Ying Ding; Rui Chen; Serena G Liao; Bao-Guo Ren; Amantha Michalopoulos; George Michalopoulos; Joel Nelson; George C Tseng; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2013-10-08       Impact factor: 4.307

6.  MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity.

Authors:  XueLi Zhang; WeiYing Zhu; JiFa Zhang; ShouJun Huo; LianMing Zhou; Zhen Gu; Min Zhang
Journal:  Biochem Biophys Res Commun       Date:  2010-04-08       Impact factor: 3.575

7.  Identification of tissue-specific microRNAs from mouse.

Authors:  Mariana Lagos-Quintana; Reinhard Rauhut; Abdullah Yalcin; Jutta Meyer; Winfried Lendeckel; Thomas Tuschl
Journal:  Curr Biol       Date:  2002-04-30       Impact factor: 10.834

8.  p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3.

Authors:  Hui Wang; Katherine Luo; Lang-Zhu Tan; Bao-Guo Ren; Li-Qun Gu; George Michalopoulos; Jian-Hua Luo; Yan P Yu
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

9.  MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.

Authors:  Marek Mraz; Dasa Dolezalova; Karla Plevova; Katerina Stano Kozubik; Veronika Mayerova; Katerina Cerna; Katerina Musilova; Boris Tichy; Sarka Pavlova; Marek Borsky; Jan Verner; Michael Doubek; Yvona Brychtova; Martin Trbusek; Ales Hampl; Jiri Mayer; Sarka Pospisilova
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

Review 10.  MicroRNAs in the DNA Damage/Repair Network and Cancer.

Authors:  Alessandra Tessitore; Germana Cicciarelli; Filippo Del Vecchio; Agata Gaggiano; Daniela Verzella; Mariafausta Fischietti; Davide Vecchiotti; Daria Capece; Francesca Zazzeroni; Edoardo Alesse
Journal:  Int J Genomics       Date:  2014-01-30       Impact factor: 2.326

View more
  17 in total

1.  miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Paola Lucia Chiara Iervolino; Esther Imperlini; Annalisa Mandola; Anna Verde; Anna Elisa De Stefano; Katia Pane; Monica Franzese; Silvia Esposito; Fulvio Basolo; Stefania Orrù; Giuliana Salvatore
Journal:  Endocrine       Date:  2019-03-29       Impact factor: 3.633

2.  Essential role of microRNA-650 in the regulation of B-cell CLL/lymphoma 11B gene expression following transplantation: A novel mechanism behind the acute rejection of renal allografts.

Authors:  Peng Jin; Hongxi Chen; Jinliang Xie; Cheng Zhou; Xiangrong Zhu
Journal:  Int J Mol Med       Date:  2017-10-17       Impact factor: 4.101

Review 3.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

Review 4.  The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.

Authors:  Chun-Jiao Song; Huan Chen; Li-Zhong Chen; Guo-Mei Ru; Jian-Jun Guo; Qian-Nan Ding
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

Review 5.  Micrornas in prostate cancer: an overview.

Authors:  Daniela Vanacore; Mariarosaria Boccellino; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Francesco Jacopo Romano; Micaela Montanari; Elvira La Mantia; Raffaele Piscitelli; Flavia Nocerino; Francesca Cappuccio; Giovanni Grimaldi; Alessandro Izzo; Luigi Castaldo; Maria Filomena Pepe; Maria Gabriella Malzone; Gelsomina Iovane; Gianluca Ametrano; Paola Stiuso; Lucio Quagliuolo; Daniela Barberio; Sisto Perdonà; Paolo Muto; Maurizio Montella; Piera Maiolino; Bianca Maria Veneziani; Gerardo Botti; Michele Caraglia; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-07-25

6.  A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients.

Authors:  M Lango-Chavarría; G K Chimal-Ramírez; M E Ruiz-Tachiquín; N A Espinoza-Sánchez; M C Suárez-Arriaga; E M Fuentes-Pananá
Journal:  Int J Oncol       Date:  2017-01-05       Impact factor: 5.650

Review 7.  Potential Therapeutic Effects of Melatonin Mediate via miRNAs in Cancer.

Authors:  Pirouz Pourmohammad; Nazila Fathi Maroufi; Mohsen Rashidi; Vahid Vahedian; Farhad Pouremamali; Yousef Faridvand; Mahsa Ghaffari-Novin; Alireza Isazadeh; Saba Hajazimian; Hamid Reza Nejabati; Mohammad Nouri
Journal:  Biochem Genet       Date:  2021-06-28       Impact factor: 1.890

8.  microRNA-605 promotes cell proliferation, migration and invasion in non-small cell lung cancer by directly targeting LATS2.

Authors:  Ying Ye; Juhua Zhuang; Guoyu Wang; Saifei He; Jing Ni; Wei Xia; Jiening Wang
Journal:  Exp Ther Med       Date:  2017-06-01       Impact factor: 2.751

9.  MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling.

Authors:  Qi You; Huining Li; Yao Liu; Yangyang Xu; Susheng Miao; Guodong Yao; Yingwei Xue; Jingshu Geng; Xiaoming Jin; Hongxue Meng
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

10.  A Bioinformatic Pipeline Places STAT5A as a miR-650 Target in Poorly Differentiated Aggressive Breast Cancer.

Authors:  Eric López-Huerta; Ezequiel M Fuentes-Pananá
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.